Indian Journal of Endocrine Surgery and Research

Register      Login

VOLUME 18 , ISSUE 1 ( January-June, 2023 ) > List of Articles


A Case Report of Ret Negative Metastatic Medullary Thyroid Carcinoma: So Close Yet So Far

Shikhil Puzhakkal, Pradeep Puthen Veetil

Keywords : Cabozantinib, Calcitonin, Medullary thyroid carcinoma, Multi kinase inhibitors

Citation Information : Puzhakkal S, Veetil PP. A Case Report of Ret Negative Metastatic Medullary Thyroid Carcinoma: So Close Yet So Far. 2023; 18 (1):9-12.

DOI: 10.5005/jp-journals-10088-11205

License: CC BY-NC 4.0

Published Online: 30-06-2023

Copyright Statement:  Copyright © 2023; The Author(s).


Medullary thyroid carcinoma (MTC) is a rare tumor arising from parafollicular c-cells. It is responsible for a fair proportion of thyroid carcinoma-related deaths. The prognosis is less favorable than papillary thyroid carcinoma. Early diagnosis and prompt therapeutic management are the best for cure. Primary surgery is the best modality of treatment for medullary thyroid carcinoma even in metastatic MTC. The currently used multi-kinase inhibitors are characterized by high toxicity and drug resistance. Here we are presenting a case of locally advanced MTC which was managed by extensive surgery without compromising the quality of life. He had a significant drop in calcitonin levels after 4 months of surgery. So, we are so close to the normal calcitonin but so far for the cure. He was started on multi-kinase inhibitor cabozantinib in view of small pulmonary metastasis but was not tolerated because of side effects.

  1. Pereira M, Williams VL, Hallanger Johnson J, et al. Thyroid cancer incidence trends in the United States: Association with changes in professional guideline recommendations. Thyroid 2020;30(8):1132–1140. DOI: 10.1089/thy.2019.0415.
  2. Randle RW, Balentine CJ, Leverson GE, et al. Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years. Surgery 2017;161(1):137–146. DOI: 10.1016/j.surg.2016.04.053.
  3. Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the American Thyroid Association Guidelines Task Force on medullary thyroid carcinoma. Thyroid 2015;25(6):567–610. DOI: 10.1089/thy.2014.0335.
  4. ESMO Guidelines Committee. ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. Ann Oncol 2022;33(7):674–684. DOI: 10.1016/j.annonc.2022.04.009.
  5. Machens A, Lorenz K, Dralle H. Time to calcitonin normalization after surgery for node-negative and node-positive medullary thyroid cancer. Br J Surg 2019;106(4):412–418. DOI: 10.1002/bjs.11071.
  6. Saltiki K, Simeakis G, Anagnostou E, et al. Different outcomes in sporadic versus familial medullary thyroid cancer. Head Neck 2019;41(1):154–161. DOI: 10.1002/hed.25463.
  7. Niederle MB, Riss P, Selberherr A, et al. Omission of lateral lymph node dissection in medullary thyroid cancer without a desmoplastic stromal reaction. Br J Surg 2021;108(2):174–181. DOI: 10.1093/bjs/znaa047.
  8. Koehler VF, Adam P, Frank-Raue K, et al. German Study Group for Rare Malignant Tumors of the Thyroid and Parathyroid Glands. Real-world efficacy and safety of cabozantinib and vandetanib in advanced medullary thyroid cancer. Thyroid 2021;31(3):459–469. DOI: 10.1089/thy.2020.0206.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.